Key Inclusion/Exclusion Criteria3

Inclusion

  • Adult patients ≥18 years old with diagnosis of gout
  • Uncontrolled gout, defined as (all required)
    • Serum uric acid (sUA) ≥7 mg/dL
    • Oral urate lowering therapy failure/intolerance
    • ≥1 ongoing gout symptom (≥1 tophus, ≥2 flares in the year prior to screening and/or chronic gouty arthritis)

Exclusion

  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency
  • eGFR <40 mL/min/1.73 m2
  • MTX contraindication/known intolerance
  • Elevated LFTs, low albumin or low blood cell counts
eGFR, estimated glomerular filtration rate; LFTs, liver function tests; MTX, methotrexate.

Family history, health literacy, and socioeconomic environment are contributing factors to gout becoming uncontrolled18,19

Two major factors contribute to uric acid buildup and crystallization18,19

Genetics
Gout runs in the family
Kidney damage
Impaired uric acid elimination
Additional contributing factors include4,18,20,21:
  • Diet and lifestyle
  • Age
  • Comorbidities
  • Metabolism
Diet is not a substitute for treatment as dietary restrictions may reduce uric acid levels by only ~1 mg/dL13,22

You are now leaving KRYSTEXXAHCP.com.

Proceed
UNMET NEED

Uncontrolled gout is a chronic and systemic disease that affects patients beyond the joints1,2

Illustrations of heart and kidneys
Stay informed for your patients and practice.
Sign Up Now

Uncontrolled gout can damage bones, joints, and vital organs3-8

The lower the sUA level, the faster urate burden can resolve1,9-13

Graphic showing how that uric acid deposits have been found in the heart, chronic kidney disease is linked to elevated sUA levels, tophi can be associated with joint damage and bone erosion, and uncontrolled gout decreases foot and ankle strength
Graphic showing how that uric acid deposits have been found in the heart, chronic kidney disease is linked to elevated sUA levels, tophi can be associated with joint damage and bone erosion, and uncontrolled gout decreases foot and ankle strength

Communicating the systemic risk beyond the pain and flares of gout to your patients can create better understanding of the importance of treatment3-8

KRYSTEXXA has not been studied to reverse damage to the kidneys, heart, or any of the body’s organs.
sUA, serum uric acid.

Need more data?

The KRYSTEXXA team is available to share more about the systemic nature of uncontrolled gout.

Request Support

Urate burden

Learn how serum uric acid levels impact urate burden and visible and nonvisible tophi.

See the Data

Learn more about patients who might benefit from KRYSTEXXA

Actor portrayal of gout and CKD patient, Richard

Richard, CKD stage 4

Occupation:
Bus driver

52-year-old with CKD stage 4; 3 flares in the last year and no visible tophi

Actor portrayal, not actual patient.

Learn About Richard
Actor portrayal of gout and CKD Stage 3b patient, Susan

Susan, CKD stage 3b

Occupation:
Dental hygienist

45-year-old with CKD stage 3b; 3 flares in the last year and 1 small tophus on her left hand for the past 2 years

Actor portrayal, not actual patient.

Learn About Susan
Real KRYSTEXXA patient, Michael, with a 30-year history of gout

Michael, CKD stage 3b

Occupation:
Architect

60-year-old diagnosed with gout over 30 years ago

Real patient.

Learn About Michael

CKD, chronic kidney disease.

IMPORTANT SAFETY INFORMATION

WARNING: ANAPHYLAXIS AND INFUSION REACTIONS, G6PD DEFICIENCY ASSOCIATED HEMOLYSIS AND METHEMOGLOBINEMIA

  • Anaphylaxis and infusion reactions have been reported to occur during and after administration of KRYSTEXXA.
  • Anaphylaxis may occur with any infusion, including a first infusion, and generally manifests within 2 hours of the infusion. Delayed hypersensitivity reactions have also been reported.
  • KRYSTEXXA should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis and infusion reactions.
  • Premedicate with antihistamines and corticosteroids and closely monitor for anaphylaxis for an appropriate period after administration of KRYSTEXXA.
  • Monitor serum uric acid levels prior to each infusion and discontinue treatment if levels increase to above 6 mg/dL, particularly when 2 consecutive levels above 6 mg/dL are observed.
  • Screen patients at risk for glucose-6-phosphate dehydrogenase (G6PD) deficiency prior to starting KRYSTEXXA. Hemolysis and methemoglobinemia have been reported with KRYSTEXXA in patients with G6PD deficiency. KRYSTEXXA is contraindicated in patients with G6PD deficiency.

CONTRAINDICATIONS:

  • In patients with G6PD deficiency.
  • In patients with history of serious hypersensitivity reactions, including anaphylaxis, to KRYSTEXXA or any of its components.

WARNINGS AND PRECAUTIONS

Gout Flares: An increase in gout flares is frequently observed upon initiation of anti-hyperuricemic therapy, including KRYSTEXXA. Gout flare prophylaxis with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended starting at least 1 week before initiation of KRYSTEXXA therapy and lasting at least 6 months, unless medically contraindicated or not tolerated.

Congestive Heart Failure: KRYSTEXXA has not been formally studied in patients with congestive heart failure, but some patients in the pre-marketing placebo-controlled clinical trials experienced exacerbation. Exercise caution in patients who have congestive heart failure and monitor patients closely following infusion.

ADVERSE REACTIONS

The most commonly reported adverse reactions (≥5%) are:

KRYSTEXXA co-administration with methotrexate trial:

KRYSTEXXA with methotrexate: gout flares, arthralgia, COVID-19, nausea, and fatigue; KRYSTEXXA alone: gout flares, arthralgia, COVID-19, nausea, fatigue, infusion reaction, pain in extremity, hypertension, and vomiting.

KRYSTEXXA pre-marketing placebo-controlled trials:

gout flares, infusion reactions, nausea, contusion or ecchymosis, nasopharyngitis, constipation, chest pain, anaphylaxis, and vomiting.

INDICATION

KRYSTEXXA® (pegloticase) is indicated for the treatment of chronic gout in adult patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.

Please see Full Prescribing Information, including Boxed Warning.

  • References
    • Doghramji PP, et al. Postgrad Med. 2012;124:98-109. 
    • Dalbeth N, et al. Lancet. 2016;388:2039-2052. 
    • Aung T, et al. Patient Prefer Adherence. 2017;11:795-800. 
    • Nickeleit V, et al. Nephrol Dial Transplant. 1997;12:1832-1838. 
    • Klauser AS, et al. JAMA Cardiol. 2019;4:1019-1028. 
    • Khanna PP, et al. J Clin Med. 2020;9:3024. 
    • Pecherstorfer C, et al. ACR Open Rheumatol. 2020;2:565-572. 
    • Ao J, et al. Clin Exp Ophthalmol. 2017;45:73-80. 
    • Perez-Ruiz F. Rheumatology (Oxford). 2009;48(suppl 2):ii9-ii14. 
    • FitzGerald JD, et al. Arthritis Care Res (Hoboken). 2020;72:744-760. 
    • Schumacher HR Jr. Cleve Clin J Med. 2008;75(suppl 5):S2-S4. 
    • Maiuolo J, et al. Int J Cardiol. 2016;213:8-14. 
    • Vargas-Santos AB, et al. Am J Kidney Dis. 2017;70:422-439. 
    • Park JJ, et al. BMJ Open. 2014;4:e005308. 
    • Dalbeth N, et al. Ann Rheum Dis. 2009;68:1290-1295. 
    • Sapsford M, et al. Rheumatology (Oxford). 2017;56:129-133. 
    • Popovich I, et al. Skeletal Radiol. 2014;43:917-924. 
    • Mandell B, et al. Arthritis Res Ther. 2018;20:286.

IMPORTANT SAFETY INFORMATION

WARNING: ANAPHYLAXIS AND INFUSION REACTIONS, G6PD DEFICIENCY ASSOCIATED HEMOLYSIS AND METHEMOGLOBINEMIA

  • Anaphylaxis and infusion reactions have been reported to occur during and after administration of KRYSTEXXA.
  • Anaphylaxis may occur with any infusion, including a first infusion, and generally manifests within 2 hours of the infusion. Delayed hypersensitivity reactions have also been reported.
  • KRYSTEXXA should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis and infusion reactions.